Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies

Daniel Abate-Daga, Steven A. Rosenberg, Richard A. Morgan

Research output: Contribution to journalArticlepeer-review

Abstract

Pancreatic cancer remains largely an incurable disease necessitating the development of novel therapeutic approaches. Adoptive immunotherapy using chimeric antigen receptor (CAR)-transduced T cells represents an alternative treatment with curative potential. We present an overview of the engineering of novel CARs targeting prostate stem cell antigen (PSCA), implications for the development of immunotherapies, and potential strategies to circumvent ontarget/ off-tumor toxicities.

Original languageEnglish (US)
Article numbere29194
JournalOncoImmunology
Volume3
Issue number6
DOIs
StatePublished - 2014

Keywords

  • Adoptive immunotherapy
  • Chimeric antigen receptors (CAR)
  • PSCA
  • Pancreatic cancer
  • Synthetic biology

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies'. Together they form a unique fingerprint.

Cite this